CHARLOTTE, N.C., April 25, 2012 (GLOBE NEWSWIRE) -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) announced today it is proud to serve as a platinum corporate sponsor of the Parkinson's Unity Walk in New York City on April 28, 2012. In addition to sponsoring the walk, Chelsea employees will also participate in the event and raise funds for Parkinson's research.
"As a sponsor of the Parkinson's Unity Walk, Chelsea is helping to fund potentially life-saving research for this devastating disease," commented Dr. Simon Pedder, president and CEO of Chelsea Therapeutics. "Chelsea is committed to helping those with a wide range of autonomic conditions, including Parkinson's disease and Neurogenic OH. We are thrilled to be raising money to support seven of the nation's largest Parkinson's organizations and their premier fundraising event."
The Parkinson's Unity Walk (PUW), a grassroots organization, began in 1994 through the dedicated efforts of patients, families, support groups, and friends who were affected by Parkinson's disease. Their main goal was to raise awareness and funds for research to find a cure for Parkinson's. The Parkinson's Unity Walk directs donated funds to increase research to find a cure. 100% of all donations made to the Parkinson's Unity Walk are distributed among the major U.S. Parkinson's disease foundations for Parkinson's disease research including the American Parkinson Disease Association, the National Parkinson Foundation, the Parkinson's Action Network, the Parkinson's Disease Foundation, The Michael J. Fox Foundation for Parkinson's Research, The Parkinson Alliance and The Parkinson's Institute and Clinical Center. To join a team, make a donation or learn more about the Parkinson's Unity Walk, please visit www.unitywalk.org.
About Chelsea Therapeutics
Chelsea Therapeutics (Nasdaq:CHTP) is a biopharmaceutical development company that acquires and develops innovative products for the treatment of a variety of human diseases, including central nervous system, rheumatoid arthritis, psoriasis and other inflammatory diseases. Founded in 2004 around its library of unique anti-inflammatory and autoimmune technology, Chelsea has further expanded its product development portfolio with early- and late-stage candidates that seek to leverage the company's development expertise and accelerate the company's drug commercialization efforts. For more information about the company, visit www.chelseatherapeutics.com.